Real-World Epidemiology of Inflammatory Bowel Disease in Italy: Treatment Patterns, Adherence, and Costs in Patients with Ulcerative Colitis Treated with Mesalazine - Scorecard - MDSpire
Clinical Scorecard: Real-World Inflammatory Bowel Disease in Six Italian Local Health Units: Mesalazine Treatment, Adherence, and Healthcare Costs in Ulcerative Colitis
IBD is described as a chronic, relapsing disorder involving intestinal inflammation and interactions among genetic susceptibility, environmental factors, and intestinal microbiota that result in an abnormal immune response.
Target Population
People identified with UC or CD in Italian healthcare administrative databases; mesalazine analyses focused on patients with UC newly initiating mesalazine and without previous mesalazine exposure.
Care Setting
Retrospective real-world analysis of reimbursed healthcare use across six Italian Local Health Units covering approximately 4 million residents in northern, central, and southern Italy.
Key Highlights
The study reports contemporary estimates of UC and CD incidence and prevalence using administrative healthcare data from six Italian Local Health Units.
Among patients with UC who initiated mesalazine, treatment adherence during follow-up was suboptimal.
Healthcare expenditures were substantial; the source identifies hospitalizations as a major contributor to the reported expenditures.
The analysis characterized demographics, comorbidities, treatment patterns, adherence, and direct SSN healthcare expenditures in routine practice.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with UC newly starting mesalazine and with no previous mesalazine exposure; they were not necessarily treatment-naive overall.
Mesalazine is widely used for mild-to-moderate UC to induce and maintain remission and is described as well tolerated. The study found suboptimal adherence during follow-up.
Clinical Best Practices
For mild-to-moderate UC, the article identifies mesalazine as a cornerstone option for induction and maintenance of clinical and endoscopic remission.
The article describes IBD treatment as directed toward rapid induction and sustained maintenance of clinical and endoscopic remission.
Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread
